These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37026883)

  • 41. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
    Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
    Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria.
    de Montjoye L; Darrigade AS; Giménez-Arnau A; Herman A; Dumoutier L; Baeck M
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):55-66. PubMed ID: 31965967
    [No Abstract]   [Full Text] [Related]  

  • 43. Clinical and laboratory parameters associated with treatment response to third-line therapies in chronic refractory urticaria: A real world study from northern India.
    Mehta H; Bishnoi A; Parsad D; Kumaran MS
    Dermatol Ther; 2022 Nov; 35(11):e15887. PubMed ID: 36181400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic urticaria phenotypes: clinical differences regarding triggers, activity, prognosis and therapeutic response.
    Curto-Barredo L; Pujol RM; Roura-Vives G; Gimenez-Arnau AM
    Eur J Dermatol; 2019 Dec; 29(6):627-635. PubMed ID: 31903953
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IgM and IgA in addition to IgG autoantibodies against FcɛRIα are frequent and associated with disease markers of chronic spontaneous urticaria.
    Altrichter S; Zampeli V; Ellrich A; Zhang K; Church MK; Maurer M
    Allergy; 2020 Dec; 75(12):3208-3215. PubMed ID: 32446275
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
    Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
    Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk factors of uncontrolled symptoms using the standard dose of second-generation H1 -antihistamines in chronic spontaneous urticaria children.
    Koosakulchai V; Yuenyongviwat A; Sangsupawanich P
    Asian Pac J Allergy Immunol; 2022 Jun; 40(2):121-125. PubMed ID: 32061244
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biologics for chronic spontaneous urticaria: toward a personalized treatment.
    Asero R; Ferrucci S; Tedeschi A; Cugno M
    Expert Rev Clin Immunol; 2022 Dec; 18(12):1297-1305. PubMed ID: 36264653
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Disease modification in chronic spontaneous urticaria.
    Maurer M; Kolkhir P; Pereira MP; Siebenhaar F; Witte-Händel E; Bergmann KC; Bonnekoh H; Buttgereit T; Fluhr JW; Frischbutter S; Grekowitz EM; Herzog L; Kiefer LA; Krause K; Magerl M; Muñoz M; Neisinger S; Nojarov N; Prins S; Pyatilova P; Ramanauskaité A; Scheffel J; Terhorst-Molawi D; Treudler R; Weller K; Zuberbier T; Metz M
    Allergy; 2024 Sep; 79(9):2396-2413. PubMed ID: 39044706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
    Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
    Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Omalizumab in severe chronic urticaria: are slow and non-responders different?
    Asero R
    Eur Ann Allergy Clin Immunol; 2021 Nov; 53(6):263-266. PubMed ID: 32914943
    [No Abstract]   [Full Text] [Related]  

  • 52. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
    Podder I; Das A; Ghosh S; Biswas D; Sengupta S; Chowdhury SN
    Dermatol Ther; 2020 Nov; 33(6):e13946. PubMed ID: 32618048
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria.
    Denman S; Smith H; Arumugakani G; Mistry A; Savic S
    Clin Exp Dermatol; 2022 Nov; 47(11):2002-2005. PubMed ID: 35775857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and Evaluation of an In-House ELISA to Detect Anti-Fc
    Sripatumtong C; Tansit T; Tuchinda P; Kanistanon D; Kulthanan K; Srinoulprasert Y
    J Immunol Res; 2022; 2022():6863682. PubMed ID: 35252460
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel biologics for treatment of chronic spontaneous urticaria.
    Casale TB
    J Allergy Clin Immunol; 2022 Dec; 150(6):1256-1259. PubMed ID: 36180286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biomarkers of chronic spontaneous urticaria and their clinical implications.
    Asero R; Cugno M
    Expert Rev Clin Immunol; 2021 Mar; 17(3):247-254. PubMed ID: 33496195
    [No Abstract]   [Full Text] [Related]  

  • 57. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment.
    Kolkhir P; Church MK; Altrichter S; Skov PS; Hawro T; Frischbutter S; Metz M; Maurer M
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):318-325.e5. PubMed ID: 31472293
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria.
    Lal Vijayalal S; Arora S; Dabas R; Janney MS; Jankal Basavarajappa S; Das NM
    Dermatol Ther; 2020 Nov; 33(6):e14397. PubMed ID: 33040395
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive features associated with chronic spontaneous urticaria recurrence.
    Toubi E; Vadasz Z
    J Dermatol; 2021 Nov; 48(11):1786-1788. PubMed ID: 34519085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation of urticaria activity score in chronic spontaneous urticaria with serum C-reactive protein level and neutrophil/lymphocyte ratio.
    Akca HM; Tuncer Kara K
    Dermatol Ther; 2020 Nov; 33(6):e14532. PubMed ID: 33176046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.